PDB39 IS INSULIN GLARGINE A COST EFFECTIVE OPTION IN TREATMENT OF PATIENTS WITH TYPE DM1 WITH BASELINE HBA1C ABOVE 8 IN COMPARISON TO NPH AND PREMIX IN POLAND?
Abstract
Authors
P McEwan A Woehl P Kawalec J Lis J Gierczynski J Walczak